You never know: Cdk inhibitors as anti-cancer drugs.

Abstract

Ever since it emerged that cyclin-dependent protein kinases catalyzed cell cycle transitions and with cancer seen as "a disease of the cell cycle," people have pursued the aim of testing kinase inhibitors as anti-cancer drugs. Quite early on, Laurent Meijer and his colleagues discovered roscovitine as a potent inhibitor of Cdk1 and the compound went into… (More)

Topics

  • Presentations referencing similar topics